Advisors Capital Management LLC Boosts Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Advisors Capital Management LLC increased its stake in Thermo Fisher Scientific by 6.7% during the first quarter, owning a total of 127,011 shares now valued at approximately $63.2 million.
• Thermo Fisher's latest quarterly earnings report showed $5.36 EPS, surpassing analysts' expectations, with a revenue of $10.86 billion for the quarter.
• The company has announced a quarterly dividend of $0.43 per share, with a dividend yield of 0.4%, scheduled for payment on October 15th.

Advisors Capital Management LLC raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 6.7% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 127,011 shares of the medical research company's stock after buying an additional 7,967 shares during the quarter. Thermo Fisher Scientific comprises 1.0% of Advisors Capital Management LLC's portfolio, making the stock its 24th largest holding. Advisors Capital Management LLC's holdings in Thermo Fisher Scientific were worth $63,201,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. MBL Wealth LLC grew its holdings in shares of Thermo Fisher Scientific by 4.3% during the first quarter. MBL Wealth LLC now owns 686 shares of the medical research company's stock worth $341,000 after purchasing an additional 28 shares in the last quarter. Geneos Wealth Management Inc. grew its holdings in shares of Thermo Fisher Scientific by 9.8% during the first quarter. Geneos Wealth Management Inc. now owns 4,666 shares of the medical research company's stock worth $2,322,000 after purchasing an additional 415 shares in the last quarter. Intech Investment Management LLC boosted its stake in Thermo Fisher Scientific by 70.7% in the first quarter. Intech Investment Management LLC now owns 13,926 shares of the medical research company's stock worth $6,930,000 after buying an additional 5,769 shares in the last quarter. Focus Partners Wealth boosted its stake in shares of Thermo Fisher Scientific by 6.0% during the first quarter. Focus Partners Wealth now owns 219,621 shares of the medical research company's stock valued at $109,284,000 after purchasing an additional 12,452 shares during the period. Finally, Flaharty Asset Management LLC purchased a new stake in shares of Thermo Fisher Scientific during the first quarter valued at approximately $68,000. Hedge funds and other institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Price Performance

TMO opened at $477.03 on Thursday. The stock has a fifty day simple moving average of $464.58 and a two-hundred day simple moving average of $452.37. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The company has a market cap of $180.13 billion, a price-to-earnings ratio of 27.59, a price-to-earnings-growth ratio of 2.58 and a beta of 0.75. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $623.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same quarter in the prior year, the company earned $5.37 earnings per share. The firm's quarterly revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio is currently 9.95%.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 400 shares of the stock in a transaction on Friday, September 5th. The stock was sold at an average price of $500.50, for a total value of $200,200.00. Following the sale, the chief executive officer directly owned 113,762 shares of the company's stock, valued at approximately $56,937,881. This represents a 0.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares in the company, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 30,066 shares of company stock valued at $14,182,963. Insiders own 0.33% of the company's stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on TMO. HSBC reissued a "hold" rating and set a $510.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Robert W. Baird upped their target price on Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a report on Thursday, July 24th. William Blair began coverage on Thermo Fisher Scientific in a report on Monday, August 18th. They set an "outperform" rating for the company. Royal Bank Of Canada set a $561.00 target price on Thermo Fisher Scientific and gave the company an "outperform" rating in a report on Tuesday, September 2nd. Finally, UBS Group upped their target price on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a report on Thursday, July 24th. Sixteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and a consensus price target of $589.38.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.